Onkološki inštitut Ljubljana (OILJ)
  • Outcome of patients with locally advanced metastatic medullary thyroid cancer and induction therapy with tyrosine kinase inhibitors in Slovenia
    Grašič-Kuhar, Cvetka ...
    The aim of our retrospective study was to evaluate the outcome of patients with metastatic medullary thyroid cancer (MTC) treated with tyrosine kinase inhibitors (TKIs) and/or chemotherapy with the ... emphasis on analysis on the cohort treated by induction TKI because of locally advanced metastatic MTC. Methods We analyzed the outcome of 30 patients (21 males, 9 females; median age 63.8 years) with metastatic MTC treated between 2000%2020. Sunitinib was used in 20 patients. Results Median progression-free survival on TKI and on chemotherapy was 10.6 (95% CI 7.1%14) months and 3.5 (95% CI 1.4%5.5) months, respectively. Median overall survival from diagnosis and from metastasis presentation was 38.2 (95% CI 4.7%71.7) months and 20.9 (95% CI 13.8%27.9) months, respectively. Eight patients (five females, three males; 58%86 years of age, median age 70 years) were treated with induction TKI because of inoperable locally advanced and metastatic MTC. The response rate to induction TKI was 50%; two patients (25%) had stable disease, and two patients (25%) had progressive disease. Conclusion Our data support a new paradigm that TKIs may be the first treatment option in selected patients with locally advanced metastatic MTC, followed by locoregional treatment with surgery and/or external beam radiotherapy. Further studies are required to consolidate the presented data.
    Vir: Advances in therapy. - ISSN 0741-238X (Vol. 38, 2021, str. 5684–5699)
    Vrsta gradiva - članek, sestavni del
    Leto - 2021
    Jezik - angleški
    COBISS.SI-ID - 81881859
    DOI

vir: Advances in therapy. - ISSN 0741-238X (Vol. 38, 2021, str. 5684–5699)

loading ...
loading ...
loading ...

Vnos na polico